Please ensure Javascript is enabled for purposes of website accessibility

Foolish Forecast: Rite Aid Revival?

By Rich Smith – Updated Nov 15, 2016 at 6:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Views you can use to get clues on tomorrow's news.

Ticktacktoe -- will tomorrow's earnings news make it three bad quarters in a row for Rite Aid (NYSE:RAD)?

What analysts say:

  • Buy, sell, or waffle? Rite Aid has shed one analyst in the last two months. Of those remaining, two rate the stock a buy, three a hold, and three a sell.
  • Revenues. First-quarter 2007 sales are expected to rise 2% in comparison with last year and reach $4.3 billion.
  • Earnings. Profits look to be headed the other way, though, with analysts predicting a 40% drop to just $0.03 per share.

What management says:
If you go by what 8-K filings the firm hands over to the SEC, you could be forgiven for thinking Rite Aid hasn't said much of interest since releasing its annual earnings results back in April. Check the firm's own website, however, and you'll see it actually has quite a lot to say. The news of most recent interest is, of course, the June sales report. There we see that Rite Aid edged out analyst sales estimates by posting 2.7% growth for the first quarter. Same-store sales were actually stronger than total firmwide sales, growing 3.6%, but that's because the company closed 1% of its stores.

In last quarter's earnings report, Rite Aid management had targeted same-store sales improvement of only 1.75% to 3.25% for this year. While there's still a long way to go between now and the end of fiscal 2007, the firm is off to a great start.

What management does:
Sales-wise, at least. It remains to be seen how profitably Rite Aid was able to make those sales. At last report, Rite Aid's rolling gross margins were back up close to the level they were at one year ago. Operating margins continue to slide, however. And although the number in the bottom-right corner of the chart below looks pretty impressive on the surface, I wouldn't give it a whole lot of weight: Last quarter's net results were almost entirely composed of one-time charges and benefits, not the least of which was a one-time tax benefit of $1.82 per share. In a quarter in which the firm earned a total of $1.83 per share, I'd say that had a pretty significant effect on the net.

Margins %

11/04

2/05

5/05

8/05

11/05

2/06

Gross

24.8%

27.4%

25.3%

25.2%

25.2%

27.2%

Op.

3.0%

3.1%

2.8%

2.7%

2.5%

2.3%

Net

0.8%

1.8%

1.6%

1.6%

1.5%

7.4%

All data courtesy of Capital IQ, a division of Standard & Poor's. Data reflects trailing-12-month performance for the quarters ended in the named months.

One Fool says:
In April, Rite Aid credited Medicare Part D as contributing significantly to its strong rise in pharmacy same-store sales. This is a relatively recent phenomenon, however. It remains to be seen how profitable all the new Medicare prescription drug business is going to be for Rite Aid. My guess? Not enough to keep that net margin at 7% plus. Then again, when you're operating in the 1.5% net margin range to begin with, it wouldn't take additional profitability to greatly magnify the net earnings produced by Rite Aid's now-growing revenues.

Competitors:

  • Walgreen (NYSE:WAG)
  • Wal-Mart (NYSE:WMT)
  • DrugMax (NASDAQ:DMAX)
  • Dollar General (NYSE:DG)
  • CVS (NYSE:CVS)

Did you miss Rite Aid's earnings report last quarter? Get the lowdown from Stephen Simpson in Rite Aid Regains Respectability.

Chat with investors interested in Wal-Mart and Dollar Tree, Motley Fool Inside Value recommendations, when you take a free trial to the newsletter and check out its discussion board.

Fool contributor Rich Smith does not own shares of any company named above.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walmart Stock Quote
Walmart
WMT
$130.06 (-2.50%) $-3.33
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$7.01 (-0.99%) $0.07
Dollar General Corporation Stock Quote
Dollar General Corporation
DG
$241.62 (0.59%) $1.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.